Ftse Mib
34.456,97
-1,06%
DAX
18.680,33
-0,46%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.089,37
-0,50%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX AIM ImmunoTech Inc (AIM) AIM ImmunoTech Inc (AIM) Notizie

AIM

AIM ImmunoTech (AIM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:AIM
DataOraFonteTitoloSimboloCompagnia
20/05/202415:15GlobeNewswire Inc.AIM ImmunoTech to Participate in Two Upcoming Investor ConferencesAMEX:AIMAIM ImmunoTech Inc
16/05/202413:30GlobeNewswire Inc.AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
15/05/202422:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:AIMAIM ImmunoTech Inc
09/05/202414:50GlobeNewswire Inc.AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
07/05/202414:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
06/05/202414:30GlobeNewswire Inc.AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®AMEX:AIMAIM ImmunoTech Inc
29/04/202414:55GlobeNewswire Inc.AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
25/04/202414:45GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
15/04/202414:55GlobeNewswire Inc.AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsAMEX:AIMAIM ImmunoTech Inc
10/04/202414:21GlobeNewswire Inc.AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerAMEX:AIMAIM ImmunoTech Inc
02/04/202413:30GlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
28/03/202413:05GlobeNewswire Inc.AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceAMEX:AIMAIM ImmunoTech Inc
26/03/202414:05GlobeNewswire Inc.AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
25/03/202414:05GlobeNewswire Inc.AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchAMEX:AIMAIM ImmunoTech Inc
15/03/202413:45GlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityAMEX:AIMAIM ImmunoTech Inc
07/03/202414:45GlobeNewswire Inc.AIM ImmunoTech Announces Launch of CEO Corner PlatformAMEX:AIMAIM ImmunoTech Inc
29/02/202414:45GlobeNewswire Inc.AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateAMEX:AIMAIM ImmunoTech Inc
21/02/202416:37Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
20/02/202422:34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:AIMAIM ImmunoTech Inc
20/02/202422:31Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
14/02/202414:55GlobeNewswire Inc.AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
08/02/202414:50GlobeNewswire Inc.AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAMEX:AIMAIM ImmunoTech Inc
24/01/202415:10GlobeNewswire Inc.AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
22/01/202414:55GlobeNewswire Inc.AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
10/01/202414:45GlobeNewswire Inc.AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
05/01/202419:32Business WireAIM Shareholders Elect All Four Company Director Nominees at 2023 Annual MeetingAMEX:AIMAIM ImmunoTech Inc
03/01/202422:24Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:AIMAIM ImmunoTech Inc
03/01/202422:24Edgar (US Regulatory)Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialAMEX:AIMAIM ImmunoTech Inc
03/01/202422:05PR Newswire (US)Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly DeniedAMEX:AIMAIM ImmunoTech Inc
29/12/202314:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:AIMAIM ImmunoTech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:AIM

La tua Cronologia

NASDAQ
UNCL
TG
I9DN
Arbutus Biopharma
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network